💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Rilonacept

CHEMBL1201830 Phase 4 Đã phê duyệt Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A fusion protein that acts as an interleukin-1 blocker, used to treat recurrent pericarditis and certain rare inflammatory conditions called cryopyrin-associated periodic syndromes. It works by trapping IL-1α and IL-1β before they can bind to their receptors and trigger inflammation.

Lĩnh vực điều trị

Cardiovascular Disease Chronic Kidney Disease Gout

Cơ chế tác dụng

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A fusion protein that acts as an interleukin-1 blocker, used to treat recurrent pericarditis and certain rare inflammatory conditions called cryopyrin-associated periodic syndromes. It works by trapping IL-1α and IL-1β before they can bind to their receptors and trigger inflammation.

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

Yes, Rilonacept is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201830. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.